Clicky

Neurocrine Biosciences, Inc.(NBIX)

Description: Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.


Keywords: Pain Diabetes Alcohol Disorders Clinical Development Cardiovascular Disease Schizophrenia Epilepsy Hormones Vascular Disease Ethers Boehringer Ingelheim Endometriosis Movement Disorders Insomnia I Diabetes Uterine Fibroid Dyskinesia Ii Diabetes Tardive Dyskinesia Transporter Fibroids Gnrh Antagonists Neurocrine Biosciences Pyrimidines Essential Tremor Gonadotropin Releasing Hormone Antagonist Stress Related Disorders

Home Page: www.neurocrine.com

NBIX Technical Analysis

12780 El Camino Real
San Diego, CA 92130
United States
Phone: 858 617 7600


Officers

Name Title
Dr. Kevin C. Gorman Ph.D. CEO & Director
Mr. Matthew C. Abernethy Chief Financial Officer
Dr. Jude Onyia Ph.D. Chief Scientific Officer
Mr. Eric S. Benevich Chief Commercial Officer
Dr. Eiry Wyn Roberts M.D. Chief Medical Officer
Dr. Dimitri E. Grigoriadis Chief Research Officer
Jane Sorensen Head of Investor Relations
Mr. Darin M. Lippoldt Chief Legal Officer & Corp. Sec.
Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer
Ms. Julie S. Cooke Chief HR Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 28.8184
Trailing PE: 182.95
Price-to-Book MRQ: 7.2969
Price-to-Sales TTM: 8.078
IPO Date: 1996-05-23
Fiscal Year End: December
Full Time Employees: 1150
Back to stocks